408 related articles for article (PubMed ID: 3676922)
1. Continuous dopaminergic stimulation in Parkinson's disease.
Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
Stocchi F; Ruggieri S; Vacca L; Olanow CW
Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
[TBL] [Abstract][Full Text] [Related]
5. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
6. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
8. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Antonini A; Jost WH
Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
[TBL] [Abstract][Full Text] [Related]
9. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN
Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868
[TBL] [Abstract][Full Text] [Related]
10. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
11. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
Drapier S; Vérin M
Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of apomorphine in movement disorders.
Colosimo C; Merello M; Albanese A
Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Stocchi F; Ruggieri S; Antonini A; Baronti F; Brughitta G; Bellantuono P; Bravi D; Agnoli A
J Neural Transm Suppl; 1988; 27():27-33. PubMed ID: 3165437
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
15. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
[TBL] [Abstract][Full Text] [Related]
16. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
17. New dopaminergic therapies for PD motor complications.
Larson D; Simuni T
Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
[TBL] [Abstract][Full Text] [Related]
18. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
20. On demand therapy for Parkinson's disease patients: Opportunities and choices.
Hauser RA; LeWitt PA; Comella CL
Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
